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The superior sensitivity and specificity associated
with the use of molecular assays has greatly improved
the field of infectious disease diagnostics by provid-
ing clinicians with results that are both accurate and
rapidly obtained. Herein, we review molecularly
based infectious disease diagnostic tests that are Food
and Drug Administration approved or cleared and
commercially available in the United States as of De-
cember 31, 2010. We describe specific assays and their
performance, as stated in the Food and Drug Admin-
istration’s Summary of Safety and Effectiveness Data
or the Office of In Vitro Diagnostic Device Evaluation
and Safety’s decision summaries, product inserts, or
peer-reviewed literature. We summarize indications
for testing, limitations, and challenges related to im-
plementation in a clinical laboratory setting for awide variety of common pathogens. The information
presented in this review will be particularly useful for
laboratories that plan to implement or expand their
molecular offerings in the near term. (J Mol Diagn
2011, 13:583–604; DOI: 10.1016/j.jmoldx.2011.05.011)
In 1986, the Food and Drug Administration (FDA) ap-
proved the first nucleic acid test, the DNA probe for
identification of Legionnaires’ disease from bacterial
culture, marketed by Gen-Probe Inc. (San Diego, CA).1
Seven years later, the FDA cleared the AMPLICOR CT
test (Roche Molecular Systems, Branchburg, NJ), the
first DNA amplification-based test for detection of Chla-
mydia trachomatis (CT) directly from a clinical sample.2
Since then, the field of clinical molecular testing in
infectious diseases has grown enormously; it repre-
sents approximately 70% of the global molecular test-
ing market.3
The FDA regulates in vitro diagnostic devices (IVDs),
which include the reagents, systems, and products used
in the molecular diagnostic assays as class I, II, or III
medical devices, with increasing regulatory oversight, to
ensure safety and effectiveness according to the risk
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JMD November 2011, Vol. 13, No. 6posed to the patient if the results are incorrect. Several
specific guidance documents regarding the classifica-
tion and review criteria of these tests are available from
the FDA Medical Devices website (http://www.fda.gov/
MedicalDevices/default.htm, last accessed December 31,
2010). The FDA also determines test complexity as high,
moderate, or waived, with most molecular IVDs being
designated as high-complexity tests. The term FDA
cleared is used for assays that are routed by a 510(k),
submission showing substantial equivalence to any as-
say already cleared by the FDA or marketed before 1976.
The term FDA approved is used when an assay is routed
by a premarket approval application to demonstrate its
efficacy and safety. A searchable database of FDA-ap-
proved or FDA-cleared assays can be accessed (http://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/
pmn.cfm, last accessed December 31, 2010), and an
updated list of FDA-cleared assays is available at the
Association for Molecular Pathology website (http://
www.amp.org/FDATable/FDATable.doc, last accessed
December 31, 2010).
Molecular infectious disease (MID) testing offers
several advantages, including rapid test results facili-
tating detection of outbreaks and, in some cases,
newly emerging strains; and sensitivity, specificity,
identification of resistant organisms, and quantifiable
correlation to disease severity, all of which contribute
to timely therapeutic clinical decisions and early infec-
tion control interventions.4 Multiplex methods can si-
multaneously detect multiple infectious agents in a sin-
gle clinical specimen. In addition, these methods are
able to identify organisms that may be difficult to iso-
late or have not been cultured by traditional methods.
Assays that provide sequence or genotype can trigger
collection of epidemiological information, track disease
outbreaks, provide strain resistance data and/or treat-
ment prognosis, and determine the method or source
and means of spread of infection.
This review complements a new Clinical and Labora-
tory Standards Institute guideline, MM19: Establishing
Molecular Testing in Clinical Laboratory Environments,
under review at the time of this article’s submission (Les-
lie Hall, personal communication in June 2011). The as-
says described were selected by reviews of several da-
tabases, including the FDA database, the Association for
Molecular Pathology website, and the PubMed database
for publications related to MIDs. Although we have at-
tempted to provide a comprehensive review of commer-
cially available FDA-cleared or FDA-approved IVDs and
platforms, we do not endorse or promote any one of these
over the other. Our review is limited to FDA-cleared or
FDA-approved assays available in the US market as of
December 31, 2010. Esoteric assays, such as those for
bioterrorism agents and emergency use, are beyond the
scope of this review. However, additional information can
be obtained at the CDC and FDA websites (http://
www.selectagents.gov/index.html and http://www.fda.gov/
MedicalDevices/Safety/EmergencySituations/ucm161496.
htm, respectively; last accessed December 31, 2010).Specific Considerations for Commercially
Available MID Assays
We focus on commonly used assays and relevant infor-
mation to assist the molecular laboratory director in assay
selection and implementation. Assays available for diag-
nosis and treatment are presented herein in four groups:
sexually transmitted diseases (STDs) (Table 1), health
care–associated infections (HAIs) and surveillance (Ta-
ble 2), respiratory tract and central nervous system (CNS,
Washington, DC) infections (Table 3), and other infec-
tions and culture confirmations [eg, hepatitis B virus
(HBV), various cultures, and ancillary assays for HAI and
surveillance] (Table 4). For each area, we highlight sev-
eral MID assays; and reference to additional FDA-cleared
assays is found in Tables 1–4.
During the FDA IVD review process, each MID assay
described in the specific product insert is approved or
cleared for a specific patient population, specimen type,
and extraction method. If a laboratory chooses to deviate
from the product insert (eg, to offer a specimen type that
is not described in the product insert), the modified assay
is considered off-label use and the laboratory is obligated
to perform a thorough validation to ensure that the mod-
ification does not alter performance claims. We present
assay sensitivity, specificity, limit of detection, dynamic
range, and percentage positive or negative agreement
with culture results, as applicable.
It is out of the scope of this article to describe the
actual process of implementation of MID testing; how-
ever, there are several excellent recent references5,6 to
assist the laboratory.
STD Data
HPV Data
More than 100 genotypes of human papilloma virus
(HPV) (Table 1) have been identified based on DNA
sequence heterogeneity, and 40 of these infect ano-
genital or ororespiratory tracts. HPV genotypes have
been divided into four oncogenic risk classes: low, inter-
mediate/high, high, and unknown. The World Health Or-
ganization’s International Agency for Research on Can-
cer (IARC), in 2009, classified HPV-16, HPV-18, HPV-31,
HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52,
HPV-56, HPV-58, and HPV-59 as high-risk (hr) HPV types
with sufficient evidence for causing cervical cancer, with
special emphasis on HPV-16 as being the most aggres-
sive type.7 Periodically, the IARC has revised its listing of
hr-HPV, and the components of the list have varied.
One prevailing viewpoint finds HPV testing differs from
other molecular assays in that analytic sensitivity for de-
tection of HPV is not the prime driver of assay perfor-
mance. A high analytic sensitivity can decrease the clin-
ical specificity, resulting in more false referrals for
colposcopy and biopsy, decreased correlation with his-
tological presence of disease, and a consequent distrust
of a positive result by the treating physician.8 This ap-
proach was further emphasized by Meijer et al,9 who set
Review of MID Assays 585
JMD November 2011, Vol. 13, No. 6forth requirements for a candidate HPV screening molec-
ular assay. A historical review of the use of HPV testing in
the screening and management of abnormal cervical
screening results is provided in a recent article by Cox,10
and we recommend reading this as part of a molecular
laboratory director’s preparation for the introduction of
HPV testing. Although some commercially available HPV
assays target both low-risk and hr-HPV types, we limit our
discussion to the application of assays detecting hr-HPV
(Table 1 contains a complete listing).
The Digene Hybrid Capture 2 (HC2) HPV DNA Test
(Qiagen, Gaithersburg, MD) has been the most widely
used molecular HPV assay in most clinical trials and has
been extensively reviewed.11 This assay is FDA ap-
proved for triage in cases of equivocal cytology results in
the presence of atypical squamous cells of undetermined
significance to determine which patients should be re-
ferred for a colposcopy and also as a screening test for
use in addition to cytology in women 30 years. The
National Cancer Institute–sponsored clinical trial of Atyp-
ical Squamous Cells of Undetermined Significance and
Low-Grade Squamous Intraepithelial Lesion Triage Study
and the Canadian Cervical Cancer Screening Trial dem-
onstrated the assay’s greater accuracy compared with
cytology alone in detecting histologically confirmed cer-
vical intraepithelial neoplasia 2/3 lesions of the cervix.12
However, Kitchener et al13 found that liquid-based cytol-
ogy appears to be closing this gap and may have an
improved sensitivity over conventional cytology.
The HC2 assay uses unlabeled single-stranded full-
genomic-length RNA probes specific for all of the types
recommended by IARC-2009 with the addition of HPV-
68. The RNA:DNA hybrids are detected by a microplate
chemiluminescent signal amplification method. The use
of full-genome probes prevents false negatives resulting
from gene deletions. The HC2 assay lacks an internal
control to evaluate sample adequacy or the presence of
interfering substances. This assay has a false-positive
rate of 7.8% for detection of hr-HPV because of the cross-
reactivity with many untargeted low-risk HPV types.14 In
an attempt to demarcate these cross-reactive false pos-
itives, which usually show a weak reaction/signal, several
groups recommended a readjustment of the cutoff value
or retesting of initial borderline samples. In 2006, the
concept of an HC2 gray zone was introduced with the
recommendation of retesting repeatedly borderline sam-
ples (relative light unit per cutoff of 1.0 to 2.5) by a
different HPV assay having a high analytic specificity.
The manufacturer subsequently changed (only slightly)
the criteria for interpretation of positive results, restricted
to samples collected in ThinPrep PreservCyt solution (Ho-
logic Inc., Bedford, MA) and not applicable to those
collected in the Digene Specimen Transport Medium
(Qiagen Inc., Valencia, CA). The Digene-recommended
algorithm for low-positive HPV results (gray or retest
zone) required a retest followed by a second retest if the
result of the first retest was 1.0 relative light unit per
cutoff. This algorithm was evaluated by Muldrew et al,15
who showed that although retesting of an initial gray zone
sample was necessary, a second retest did not offer
advantages over the first retest. Another group16 showedthat increasing the HC2 positive cutoff value to 2.0 rela-
tive light unit would improve clinical specificity, with only
a minimal reduction in clinical sensitivity. However, these
recommendations are not part of the FDA approval of this
assay.
The Cervista HPV HR (Hologic, Inc., Bedford, MA)
assay uses manual extraction with a single-well Invader
Biplex technology format that simultaneously detects
HPV and a Histone H2be DNA internal control in the same
reaction. The assay is an isothermal signal amplification
method using Invader chemistry. The probe pools detect
14 HPV types (IARC-2009 12 hr-HPV plus HPV-66 and
HPV-68) and identify type-specific single-nucleotide
polymorphisms, effectively decreasing cross-reactivity
with low-risk types and false-positive results. The assay
only requires 2.0 mL of sample (half the requirement of
Digene HC2). The inclusion of an internal control is a
quality control measure that differentiates between a true
negative and a sample with insufficient DNA present and
is also a verification of the procedure. The same sample
specimen used in the Cervista HPV HR may then be
reflexed to the Cervista HPV 16/18 genotyping assay,
which specifically identifies the presence of HPV types 16
and 18, now implicated in approximately 70% of cases
progressing to cancer.17,18
In a postapproval clinical study (SHENCCAST II, con-
ducted in China) comparing the HC2 with the Cervista
hr-HPV assays, the HC2 showed better sensitivity (95.6%
versus 92.9%), whereas the Cervista assay demon-
strated a statistically significantly higher specificity
(91.1% versus 88.6%; P  0.05).19
HPV testing is performed predominantly on liquid-
based cytology samples, and sample collection is deter-
mined by the method in use. The HC2 assay has been
validated for use with the Digene Specimen Transport
Medium and the ThinPrep PreservCyt solution. Use of
other collection media (eg, SurePath liquid cytology me-
dium) is considered unapproved off-label use. The Cerv-
ista assay has been validated for use with the PreservCyt
solution. The typical turnaround time is 1 to 3 days, de-
pending on the platform and availability of automation.
In addition to molecular assays for the detection of
HPV, the FDA has also approved the Cervista HPV 16/18
genotyping assay, briefly mentioned earlier (Hologic,
Inc.). This assay is based on the same Invader technol-
ogy as the Cervista hr-HPV detection test and, as indi-
cated by its name, specifically detects and distinguishes
HPV types 16 and 18. For cytology-negative, hr-HPV–
positive women, HPV 16/18 genotyping can be used to
determine who should be referred for immediate colpos-
copy. If the HPV 16/18 genotyping test result is negative,
then cytology and hr-HPV testing are recommended to
be repeated in 12 months. The American Society for
Colposcopy and Cervical Pathology Consensus Confer-
ence Recommendations for HPV 16/18 detection do not
recommend the use of HPV genotyping in women with
atypical squamous cells of undetermined significance
who test positive for hr-HPV. Alternatively, the American
Society for Colposcopy and Cervical Pathology recom-
mends that these women are referred to colposcopy
(American Society for Colposcopy and Cervical Pathol-
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Organism Specimen/sample type Assay/platform (FDA no.)
HPV Cervical cytology specimen in ThinPrep PreservCyt and cervical
cytology specimen in Specimen Transport Medium
Digene HC2 HPV DNA Test (P890064/S006)†
Cervical cytology specimen in ThinPrep PreservCyt and cervical
cytology specimen in Specimen Transport Medium
Digene HC2 High-Risk HPV DNA typing kit
(P890064/S009)†
Cervical cytology specimen in ThinPrep PreservCyt Cervista HPV HR (P080014)¶
Cervical cytology specimen in ThinPrep PreservCyt Cervista HPV 16/18 (P080015)¶
HSV Vaginal lesion swab only (not for prenatal screening or in
females 18 years); collected in Copan Universal
Transport Medium or identical Copan- manufactured
media formulation; an extractable sample processing
control target is added to the specimen before lysis
MultiCode RTx HSV 1&2 Kit (K100336)††
MagNA Pure LC Total NA Kit and Magna
Pure Instrument LightCycler 1.2‡‡
CT Endocervical (female) and urethral (male) swabs; urine
specimens (male and female); gynecological specimens
collected in BD SurePath preservative fluid
BD ProbeTec CT Qx Amplified DNA Assay
(K090824, K091724, K081824)§§
Endocervical and vaginal (female) and urethral (male)
swabs; urine specimens (male and female); patient-
collected vaginal swab specimen is also accepted
APTIMA Assay for Chlamydia trachomatis
(K043072, K053446, K061413, K063451)¶¶
Specimen that has been processed and tested positive by
PACE 2 system for CT
PACE 2 CT (K920302)¶¶
Digene Cervical Sampler or Dacron swab placed in Digene
Specimen Transport Medium
Digene HC2 CT-ID DNA Test (K990023,
K010892)†
Endocervical (female) and urethral (male) swabs; urine
specimens (male and female)
COBAS AMPLICOR (CT/NG) Test (K973707,
K973718, K070174, K053287)‡‡
NG Cervical and vaginal (female) and urethral (male) swabs;
urine (male and female); PreservCyt specimens; Surepath
specimens
BD ProbeTec GC QX Amplified DNA Assay
(K081825, K090971)§§
NG Vaginal and cervical swabs; urethral swabs (male); urine
(male and female); PreservCyt specimen
APTIMA Assay for NG (K043144, K061509,
K062440, K063664)¶¶
Specimen that has been processed and tested positive by
PACE 2 system for NG
PACE 2 NG (K920301)¶¶
Cervical specimens collected using Digene Cervical
Sampler and Digene Swab Specimen Collection kit
Digene HC2 GC-ID DNA Test (K981485,
K010893)†
Cervical (female) and urethral (male) swabs; urine (male) AMPLICOR CT-NG for NG (K974503,
K974342, K070172, K053289)‡‡
CT-NG combined Vaginal (female) and urethral (male) swabs; urine (male and
female); patient-collected vaginal swab specimen
RealTime CT-NG assay (K092704,
K080739)***
Endocervical (female) and urethral (male) swabs; urine
specimens (male and female)
BD ProbeTec ET CT-GC (K012351)§§
CT-NG combined Endocervical (female) and urethral (male) swabs; urine
specimens (male and female)
APTIMA COMBO 2 (K003395, K022874,
K032554, K043224, K060652)¶¶
Endocervical (female) and urethral (male) swab specimens
collected with the PACE Specimen Collection kits
PACE 2C CT-NG (K940979)¶¶
Cervical specimens collected using Digene HC2 DNA
Collection Device or Digene Female Swab Specimen
Collection Kit
Digene HC2 CT/GC Dual DNA Test
(K981567, K010891)†,†††
HIV-1 Human plasma specimens (ACD-A and EDTA) RealTime HIV-1 assay (BP060002)*** and
m2000 (m2000sp  2000rt)(table continues)
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Method Target
Linear range (%)*
Sensitivity Specificity
Hybridization protection assay with signal
amplification using microplate
chemiluminescence hybrid capture of
RNA-DNA hybrid
RNA probe cocktail for 13 hr
types (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, and
68) and 5 low-risk types (6,
11, 42, 43, and 44)
93.0‡ 61.1
Hybridization protection assay with signal
amplification using microplate
chemiluminescence hybrid capture of
RNA-DNA hybrid
RNA probe cocktail to detect
13 hr-HPV types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56,
58, 59, and 68)§
93.0‡ 61.1
Invader technology E6/E7/L1; cocktail of 14 hr-
HPV DNA probes (16, 18,
31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68);
human histone 2 gene
(internal control)
92.8 67.2 (aged 30
years)
Invader technology Cocktail of two types of
sequence-specific DNA
probes**; human histone 2
gene (internal control)
PPA, 85.7 (65.4–95.0) NPA, 95.9 (94.9–96.7)
Real-time PCR using isoC:isoG synthetic
DNA bp technology
Glycoprotein gene segment
of HSV-1 and HSV-2
HSV-1, 92.4 HSV-1, 98.3
HSV-2, 95.2 HSV-2, 93.6
Strand displacement amplification Alternate region of the
cryptic plasmid
94.5 98.9
Transcription-mediated amplification 23S rRNA 95.6 98.8
Probe competition assay; CT confirmation
test
23S rRNA 91.7 98.5
Hybrid capture RNA probe cocktail
complementary to CT
genomic DNA; cryptic
plasmid
92.3–97.7 98.2–98.6
PCR Cryptic plasmid 92.9–94.1 94.7–98.4
Strand displacement amplification Pilin gene 99.3 99.4
Transcription-mediated amplification 16S rRNA 92.3 99.8
Probe competition assay; GC
confirmation test
rRNA 95.1 98.7
Hybrid capture RNA probe cocktail
complementary 0.5% of
the NG genome, cryptic
plasmid
92.6–95.2 98.5–98.9
PCR M.NgoPII putative methyl
transferase gene of NG
95.9–96.5 98.7–97.3
Real-time PCR CT, cryptic plasmid CT, 92.5–97.8 CT, 98.3–99.8
NG, Opa gene NG, 87.0–100 NG, 99.3–100
Strand displacement amplification CT, cryptic plasmid CT, 92.0 CT, 94.9
GC, Pilin gene GC, 96.1 GC, 98.2
Transcription-mediated amplification CT, 23S rRNA CT, 95.2–96.5 CT, 97.6–98.7
NG, 16S rRNA NG, 96.5–99.1 NG, 98.4–99.4
Probe competition assay rRNA CT-NG, 96.8 CT-NG, 93.6
Hybrid capture CT-GC RNA probe cocktail CT, 96.1 CT, 98.7
GC, 93.0 GC, 99.1
Real-time RT-PCR Integrase region in pol gene 40–10,000,000
copies/mL (HIV-1
groups M, N, and O)(table continues)
NA; NP
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asccp.org/pdfs/consensus/clinical_update_20090408.pdf,
last accessed December 31, 2010).
CT and NG Data
CT and Neisseria gonorrhoeae (NG) are the most common
cause of bacterial STDs, and both can cause urogenital
tract infections ranging from acute to asymptomatic dis-
ease. CT is an obligate intracellular bacterium compris-
ing 15 serovars, whereas NG is a fastidious intracellular
diplococcus. Significant underreporting of disease can
occur as the result of silent infections affecting the repro-
ductive age group. Identification and treatment is impor-
tant to prevent the sequelae of infection, such as infertil-
ity, chronic pain, and pelvic inflammatory disease.
Urogenital specimens commonly exhibit amplification
Table 1. Continued
Organism Specimen/sample type
Plasma extracted from blood collected us
ACD‡‡‡
Plasma separated from blood collected u
HIV-1 Plasma extracted from blood collected us
ACD‡‡‡
Plasma or serum
Plasma or serum
Plasma or serum
HIV-1 drug
resistance¶¶¶
Plasma samples from blood collected in E
Plasma samples from blood collected usi
anticoagulants
*Sensitivity, specificity, linear range, and percentage positive or negative ag
†Obtained from Qiagen, Gaithersburg, MD.
‡Atypical squamous cells of undetermined significance referral Papan
§Cross-reacts with HPV types 40, 53, and 66.
¶Obtained from Hologic, Madison, WI.
Cross-reacts with HPV types 67 and 70.
**Cross-reacts with high levels of HPV type 31.
††Obtained from EraGen Biosciences, Madison, WI.
‡‡Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
§§Obtained from BD Diagnostics, Sparks, MD.
¶¶Obtained from Gen-Probe, Inc., San Diego, CA.
Depending on brush or swab specimens.
***Obtained from Abbott Molecular, Inc., Des Plaines, IL.
†††This assay is indicated for use as an initial test and requires confir
‡‡‡ACD specimens will yield approximately 15% lower test results be
§§§Obtained from Siemens Healthcare Diagnostics, Deerfield, IL.
¶¶¶Provides information on resistance to nucleoside and nonnucleosi
Obtained from Celera Diagnostics, Alameda, CA.
****Obtained from Applied Biosystems, Foster City, CA.
ACD-A, anticoagulant citrate dextrose solution A; bDNA, branched Dinhibition. The inhibitory substances can be removed byincluding nucleic acid purification steps in the sample
preparation. The sample preparation protocols vary
among the commercially available assays, ranging from
the use of crude lysates (AMPLICOR) to purified nucleic
acids. The Roche AMPLICOR assay uses an amplifica-
tion control in the sample that allows for detection of
inhibitory substances. This control consists of a plasmid-
containing CT primer binding sites and a randomized
internal sequence. The BD ProbeTec (BD Diagnostics,
Sparks, MD) uses 1000 copies of a linearized NG DNA
containing plasmid as the internal amplification control.
Commercially available assays for CT and NG (Table
1) use target amplification methods, with the one excep-
tion being the Digene HC2 assay, which uses a signal
amplification method with an RNA probe cocktail com-
plementary to approximately 39,300 bp (4%) of the Chla-
mydia genomic DNA and one probe complementary to
Assay/platform (FDA no.)
TA or AMPLICOR HIV-1 MONITOR test, version 1.5
(BP950005/4)‡‡ and COBAS AMPLICOR
HIV-1 MONITOR test, version 1.5
(BP950005)‡‡
DTA COBAS AmpliPrep/COBAS TaqMan HIV-1
test (BP050069/0)‡‡ and COBAS
AmpliPrep/COBAS TaqMan‡‡
TA or VERSANT HIV-1 RNA 3.0 Assay (bDNA)
(BP000028/0)§§§ and VERSANT Molecular
System§§§
APTIMA HIV RNA Qualitative Assay
(BL103966/5040)¶¶
Procleix ULTRIO Assay¶¶
Procleix HIV-1, HCV, and/or HBV
Discriminatory Assays (BL 125113/33)¶¶
COBAS AmpliScreen HIV-1 Test (BL 125059/
37)‡‡
ViroSeq HIV-1 Genotyping System
(BK030033) and ABI 3100/3130 capillary
electrophoresis platform****
D or EDTA TRUGENE HIV-1 Genotyping Kit
(BK090077)§§§ and OpenGene DNA
Sequencing System§§§
(table continues)
with culture data are sourced from FDA submission material or product inserts.
stain population, Kaiser Study, PreservCyt solution specimens.
with the individual MID assays.
f the dilution effect of 1.5 mL ACD in the collection tube.
rse transcriptase and protease inhibitors.
A, negative predictive accuracy; PPA, positive predictive accuracy.ing ED
sing E
ing ED
DTA
ng AC
reement
icolaou
mation
cause o
de reve100% of the cryptic plasmid. Nucleic acid amplification
Review of MID Assays 589
JMD November 2011, Vol. 13, No. 6testing assays typically increase sensitivity by targeting
multiple copy genes or plasmids. For CT, the targets
include cryptic plasmid DNA present in nearly all sero-
vars (5 to 10 copies), genes such as omp1, and ribo-
somal RNA (rRNA; 16S and 23S). For NG, targets include
the cytosine methyl transferase gene (M.NgoPII), the Opa
gene, Piv-1 genes, and 16S and 23S rRNA. The speci-
men type approved for CT and NG testing is assay spe-
cific (Table 1) and includes urethral swab and urine for
males and endocervical/cervical samples, vaginal
swabs, urine, and PreservCyt (Hologic, Inc.) specimens
for females. A male first-void urine specimen and vaginal
swabs are considered optimal specimens, according to
the Association of Public Health Laboratories (http://
www.aphl.org/aphlprograms/infectious/std/documents/
ctgclabguidelinesmeetingreport.pdf, last accessed De-
Table 1. Continued
Method Tar
End point RT-PCR 142 bp in high
region of Ga
Real-time RT-PCR Gag gene
bDNA technology Pol gene
Transcription-mediated amplification Highly conserv
HIV-1 RNA
Transcription-mediated amplification Highly conserv
HIV-1 RNA, H
and HBV DN
RT-PCR Gag gene
RT-PCR, population sequence analysis HIV-1 subtype
gene and pa
sequence of
transcriptase
the pol gene
RT-PCR, population sequence analysis protease gene
the reverse t
regionscember 31, 2010).The AMPLICOR NG detection kit (Roche Molecular
Diagnostics, Pleasanton, CA) targets the M.NgoPII gene,
whereas the BD ProbeTec ET CT/GC targets the cryptic
plasmid of CT and the Piv-1 gene of NG. Both of these
assays have cross-reactivity with some Neisseria species.
Confirmatory testing using a different gene target is an
option in such instances. Cross-reactivity has not been
reported for the Real Time CT/NG (Abbott Laboratories,
Des Plaines, IL), APTIMA COMBO 2 (Gen-Probe Inc., San
Diego, CA), and PACE 2 (Gen-Probe Inc.) assays.20
Coinfection with CT and NG occurs in many patients.
Simultaneous detection of both organisms in a single test
is achieved by several assays (Table 1). The APTIMA
COMBO 2 is a second-generation assay that uses target
capture with transcription-mediated amplification and
chemiluminescent hybridization protection. In contrast to
Linear range (%)*
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JMD November 2011, Vol. 13, No. 6bacterial DNA, transcription-mediated amplification am-
plifies specific regions of the 23S rRNA/16S rRNA. The
APTIMA COMBO 2 assay does not have an internal con-
trol; however, it uses target capture technology, which
removes inhibitors. The assay is a dual kinetic assay, with
one signal scoring for CT and the second signal scoring
for NG. Assays that target bacterial rRNA rather than
Table 2. HAI Assays
Organism
Specimen/sample
type
Assay/platform
(FDA no.) Method
MRSA/SA
(screening,
surveillance)
Lesion (skin/soft
tissue) double
swab
Xpert MRSA/SA
SSTI
(K080837)†
and
GeneXpert
System†
Real-time
PCR
Nasal swabs
(surveillance)
Xpert MRSA
(K070462)†
and
GeneXpert
System†
Real-time
PCR
Nasal swabs
(surveillance)
BD GeneOhm
MRSA ACP
(K093346)‡
and
SmartCycler†
Real-time
PCR
Nasal swabs
(presurgical
screen)
Xpert SA Nasal
Complete
(K100822)†
and
GeneXpert
System†
Real-time
PCR
Nasal swabs
(surveillance)
LightCycler
MRSA
Advanced
test
(K091409)§
and
LightCycler
2.0
Real-time
PCR
Enterococcus Rectal swab
(surveillance)
Xpert vanA
(K092953)†
and
GeneXpert
System†
Real-time
PCR
C. difficile Unformed
(liquid or soft)
stools
Xpert C. difficile
(K091109)†
and
GeneXpert
System†
Real-time
PCR
Prodesse
ProGastro Cd
(K090239)¶
Multiplex
real-tim
PCR
BD GeneOhm
Cdiff Assay
(K081920)‡
Real-time
PCR
Illumigene C.
difficile
(K091109)
LAMP
technol
LAMP, loop-mediated amplification; PaLoc, pathogenicity locus; SCC
*Sensitivity, specificity, and percentage positive or negative agreemen
†Obtained from Cepheid, Sunnyvale, CA.
‡Obtained from BD Diagnostics-Infectious Diseases, LaJolla, CA.
§Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
¶Obtained from Gen-Probe Prodesse, Inc., Waukesha, WI.
Obtained from Meridian Bioscience, Inc., Cincinnati, OH.plasmid DNA have a greater ability to detect lower con-centrations of organisms because of the presence of up
to a 1000-fold greater amount of RNA than plasmid DNA
in the infected cell.
Cryptic plasmid–based detection assays could yield
false-negative results because CT strains without the
plasmid or with deletions in the plasmid have been de-
scribed (the Swedish variant, with a 377-bp fragment
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assays that target the deleted region, whereas those
assays that target outside of this region or the chromo-
somal regions detect the mutant strain.21 The BD Pro-
beTec assay is able to detect the CT Swedish variant
because the cryptic plasmid target is outside the area of
deletion. The newer Abbott RealTime CT/NG assay, FDA
cleared in June 2010, includes an additional 140-bp
cryptic plasmid target outside of the 377-bp deletion
area. The Abbott RealTime CT/NG assay also contains a
small fragment of noninfectious linearized DNA plasmid
for use as an internal control throughout the sample prep-
aration process.
A low prevalence of STDs in a specific population may
reduce the positive predictive value of the molecular re-
sult. However, the test can be repeated with a separate
aliquot of the same specimen or a second specimen and
a different test method and/or a different target to confirm
the positive result.20 The efficacy of this strategy is
debatable.22
HIV-1 Assay
Qualitative assays, such as the Procleix ULTRIO and
Discriminatory HIV-1/HCV/HBV assays (Gen-Probe Inc.)
and the COBAS AmpliScreen HIV-1 test (Roche Molecu-
lar Systems, Pleasanton), are available for donor screen-
ing applications. The transcription-mediated amplifica-
tion–based APTIMA HIV-1 RNA qualitative assay (Gen-
Probe Inc.) can be used for diagnosing acute and
primary infections and can detect infection before sero-
conversion and confirm infections in individuals when
antibody test results are positive.23,24 However, in this
segment, we will focus on the quantitative and genotyp-
ing assays that are the main HIV-1–related assays per-
formed in the Molecular Diagnostics Laboratory.
HIV-1 viral load assays are important for monitoring
HIV-1–infected individuals, predicting the progression of
HIV disease, and monitoring antiretroviral treatment.25,26
HIV-1 is classified into three major groups (ie, M, N, and
O). Group M is the most prevalent and is sub-classified
into seven subtypes (ie, A–D and F–H) that are geograph-
ically distinct. Several commercial kits are available for
quantitative determination of HIV viral load to assess pa-
tient prognosis during antiretroviral therapy (Table 1).
Ascertaining the viral load is a prerequisite to initiating
drug therapy in adherence to FDA guidelines and serves
to evaluate the efficacy of antiretroviral therapy (http://
www.aidsinfo.nih.gov/guidelines, last accessed Decem-
ber 31, 2010). In 1996, the AMPLICOR HIV-1 MONITOR
test (Roche Molecular Systems) was the first FDA-ap-
proved quantitative HIV end point–based RT-PCR assay.
Quantification of HIV-1 RNA copy number is determined
by comparing optical density readings of the HIV-1 signal
with an external quantitation standard signal, which has a
known copy number input. However, a small dynamic
range of 400 to 750,000 copies/mL (or 50 to 100,000
copies/mL for the ultrasensitive method) limits the assay.
Recently, real-time RT-PCR HIV assays with options of
automation, closed-system platform characteristics,
broad dynamic range, and good specificity have becomecommercially available.27 By using the COBAS AmpliP-
rep/COBAS TaqMan HIV-1 Test (Roche Molecular Sys-
tems), patient specimens are extracted on the COBAS
AmpliPrep instrument and amplification/detection occurs
on the COBAS TaqMan Analyzer. The assay targets the
conserved region in the gag gene, which is prone to a
high level of mutation and is only intended for the detec-
tion of group M subtypes of HIV-1. Calibration is not
required because specific calibration values and pre-
defined assay control ranges are included with each kit
and because uracil-N-glycosylase reduces the risk of
carryover contamination. Initial underestimations regard-
ing quantification of HIV-1 group M non-B subtypes,
when compared with the COBAS AMPLICOR HIV-1
MONITOR Version 1.5 and the Abbott RealTime HIV-1
assay, have been reported.28–32 A second version of the
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test version
2.0 (Roche Molecular Systems) was recently approved.
This assay improves the underquantification and subtype
inclusivity issues present with the original assay. The
version 2.0 assay uses a two-target approach with the
combination of the new ltr primer-probe set with the orig-
inal gag primer-probe set to detect the various group M
HIV-1 subtypes A–D and F–H and group O. The assay
has a quantitation range of 20 to 107 RNA copies/mL.33,34
With the Abbott RealTime HIV-1 kit (Abbott Molecular,
Inc., Abbott Park, IL), patient specimens are extracted on
the m2000sp instrument and detected on the m2000rt
instrument. The assay allows for flexibility in the sample
input volumes and detects both group M and group O
HIV-1 subtypes. In contrast to these real-time PCR-based
assays, the VERSANT HIV-1 RNA 3.0 Assay (Siemens
Health Care Diagnostics, Deerfield, IL) uses branched
DNA chemistry, which relies on signal amplification. The
assay has a lower risk of contamination because of the lack
of amplicon production, and the VERSANT HIV-1 RNA 3.0
Assay has been validated for samples containing group M
subtypes A–G (in 2002, subtype E was still believed to be a
true subtype); however, it has decreased sensitivity com-
pared with target amplification assays.35,36
During treatment of HIV infections, mutant HIV-1
strains emerge that are resistant to one or more drugs.37
The identification of viral resistance genotypes allows
treatment strategies to be modified.38 Retrospective and
prospective intervention-based studies38–41 have pro-
vided evidence supporting the clinical utility of genotype
testing for resistance, and this is recommended by the
International AIDS Society–USA panel for selecting new
regimens after treatment failure and monitoring therapy
for pregnant women. Genotype testing should also be
considered before initiation of therapy for acute infections
and for treatment-naïve patients with established
infection.38
Two genotyping systems are commercially available:
TRUGENE HIV-1 Genotyping Kit (Siemens Diagnostics,
Tarrytown, NY) and ViroSeq HIV-1 Genotyping Systems
(Celera Diagnostics, Alameda, CA). The ViroSeq kit pro-
vides reagents for viral RNA isolation from plasma, and
both kits provide reagents for RT-PCR and sequenc-
ing.39,40,42 Typically, the entire protease and the 5= re-
verse transcription coding regions of the pol gene are
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Organism Specimen/sample type Platform/assay (FDA no.)
Respiratory virus panel: influenza A/H1 and
A/H3; influenza B; adenovirus; RSV;
metapneumovirus (hMPV); parainfluenza
(hPIV) 1, 2, and 3; and rhinovirus
Nasopharyngeal swab xTAG Respiratory Viral Panel (K063765)†
Respiratory virus panel: influenza A and B
and RSV
Nasopharyngeal swab, cultured
clinical specimens
Verigene Respiratory Virus Nucleic Acid Test
(K083088)‡ and Verigene Respiratory
Virus Nucleic Acid Test on the Verigene
SP system (K092566)‡
Nasopharyngeal swab ProFlu (K073029, K081030, K092500)§ and
SmartCycler¶
Respiratory virus panel: influenza A and B
and RSV
Nasopharyngeal swab Simplexa Flu A/B and RSV (K102170);
MagNA Pure LC Instrument and the
MagNA Pure Total Nucleic Acid Isolation
Kit** or a Qiagen QIAamp Viral RNA Mini
Kit†† and 3M Integrated Cycler‡‡
Respiratory virus: influenza A/H1N1-2009 Nasopharyngeal swabs, nasal
swabs, NPAs
Simplexa Influenza A H1N1 (2009)
(K100148); MagNA Pure LC Instrument
and the MagNA Pure Total Nucleic Acid
Isolation Kit** or a Qiagen QIAamp Viral
RNA Mini Kit†† and 3M Integrated Cycler‡‡
Respiratory virus: influenza A/H1N1-2009 Nasopharyngeal swabs and
nasal swabs
CDC Human Influenza Virus Real-Time RT-
PCR Detection and Characterization Panel
(K101564)§§ and Applied Biosystems 7500
Fast Dx Real-Time PCR Instrument¶¶
Respiratory virus panel: seasonal influenza
A/H1, A/H3, and A/H1N1-2009
Nasopharyngeal swab ProFAST (K101855)§ and SmartCycler¶
Respiratory virus: influenza A/H5 (Asian
lineage)
Nasopharyngeal and throat
swabs
JBAIDS Influenza A subtype A/H5 (Asian
lineage) (K100287) and JBAIDS
Instrument
Respiratory virus: hPIV Nasopharyngeal swab ProParaFlu (K091053)§ and SmartCycler¶
Respiratory virus: hMPV Nasopharyngeal swab Pro hMPV (K082688)§ and SmartCycler¶
Respiratory virus: adenovirus Nasopharyngeal swab ProAdeno (K102952)§ and SmartCycler¶
Enterovirus CSF Xpert EV (K061062) and GeneXpert System¶
CSF NucliSENS EasyQ Enterovirus (K063261)***
and NucliSENS EasyQ System
MTB Sputum and bronchial
specimens
AMPLIFIED MTD (Mycobacterium
Tuberculosis Direct) Test
(P940034/S008)†††
(table continues)
*Sensitivity, specificity, and percentage positive or negative agreement with culture data are sourced from FDA submission material or product inserts.
†Obtained from Luminex Corporation, Austin, TX.
‡Obtained from Nanosphere, Inc., Northbrook, IL.
§Obtained from Gen-Probe Prodesse, Inc., Waukesha, WI.
¶Obtained from Cepheid, Sunnyvale, CA.
Obtained from Focus Diagnostics, Inc., Cypress, CA.
**Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
††Obtained from Qiagen, Gaithersburg, MD.
‡‡3M, St Paul, MN.
§§Obtained from the CDC, Atlanta, GA.
¶¶Obtained from Life Technologies Inc., Carlsbad, CA.
Obtained from the Department of Defense.
***Obtained from bioMérieux Inc., Durham, NC.
†††Obtained from Gen-Probe, Inc., San Diego, CA.
hMPV, human metapneumovirus; hPIV, human parainfluenza virus; NASBA, nucleic acid sequence-based amplification; NPA, nasopharyngeal aspirate.
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Method Target Sensitivity (%)* Specificity (%)*
RT-PCR, allele-specific primer
extension, tag sorting
Matrix gene of influenza A, Hemagglutinin
gene of influenza A/H1 and A/H3
Influenza A, 96.4 Influenza A, 95.9
Influenza B, adenovirus, RSV A/B
metapneumovirus
Influenza A/H1, 100 Influenza A/H1, 100
Parainfluenza 1, 2, and 3; and rhinovirus Influenza A/H3, 91.7 Influenza A/H3, 98.7
Influenza B, 91.5 Influenza B, 96.7
RSV A, 100 RSV A, 98.4
RSV B, 100 RSV B, 97.4
Adenovirus, 78.3 Adenovirus, 100
hMPV, 96 hMPV, 98.8
hPIV 1, 100 hPIV 1, 99.8
hPIV 2, 100 hPIV 2, 99.8
hPIV 3, 84.2 hPIV 3, 99.6
Rhinovirus, 100 Rhinovirus, 91.3
Multiplex RT-PCR multiplex gold
nanoparticle hybridization
technology Verigene System‡
Influenza A matrix gene Influenza A, 99.2 Influenza A, 90.1
Influenza B NS and matrix genes Influenza B, 96.8 Influenza B, 98.5
L and F genes of RSV RSV, 89.8 RSV, 91.5
Multiplex real-time RT-PCR
TaqMan chemistry
Influenza A matrix gene Influenza A, 100 Influenza A, 92.6
Influenza B non-structural NS1 and NS2
genes
Influenza B, 97.8 Influenza B, 98.6
RSV polymerase gene RSV, 89.5 RSV, 94.9
Real-time RT-PCR Target RNA of highly conserved region of
matrix protein genes of influenza A and
B and RSV
Influenza A, 100 Influenza A, 99.3
Influenza B, 100 Influenza B, 99.8
RSV, 98 RSV, 96.9
Real-time PCR Influenza A matrix gene and unique
region in Hemagglutinin gene of 2009
H1N1 influenza virus
% positive agreement
for swabs, 100;
NPA, 100
% negative agreement
for swabs, 92.5;
NPA, 96.1
Real-time PCR Influenza A matrix gene and
Nucleoprotein gene specific for 2009
H1N1 and Hemagglutinin gene specific
for 2009 H1N1
96 96
Real-time RT-PCR Target RNA of conserved region of
Hemagglutinin gene
% positive agreement
for A/H1, 100; A/H3,
100; A/H1N1-2009,
95.4
% negative agreement
for A/H1, 99.0; A/
H3, 99.0; A/H1N1-
2009, 100
Real-time RT-PCR Two target RNA sequences 5= and 3= of
the Hemagglutinin precursor cleavage
site within the conserved regions of the
Hemagglutinin gene of influenza A/H5
(Asian lineage) virus
96.9–100 95.3–97.1
Multiplex real-time RT-PCR
TaqMan chemistry
Conserved regions of Hemagglutinin-
Neuraminidase gene of hPIV 1, 2, and 3
hPIV-1, 88.9 hPIV-1, 99.9
hPIV-2, 96.3 hPIV-2, 99.8
hPIV-3, 97.3 hPIV-3, 99.2
Real-time RT-PCR TaqMan
chemistry
hMPV: Nucleocapsid gene % positive agreement,
94.1
% negative
agreement, 99.3
Multiplex real-time PCR TaqMan
chemistry
Adenovirus serotypes 1–51, Hexon gene 97.5 95.6
Real-time PCR Consensus region of enterovirus, 5= UTR
between nucleotides 452 and 596
96.3–100 97.0–97.2
NASBA Enterovirus RNA 70.9–100 99.3–100
Transcription- mediated
amplification, hybridization
protection assay
Mycobacterial 16S rRNA 96.9 100
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as a sequencing template for multiple primers that gen-
erate a consensus sequence. Software is available for
comparing the consensus with a known reference, to
determine any mutations present, based on which treat-
ment options are made available. These are kept current
by a panel of HIV experts and recommendations of the
International AIDS Society–USA panel.37,43,44 Report-
edly, genotyping assays may have limitations of sensitiv-
ity in detecting a minority variant species in a patient.45 In
addition, potential mutations may be missed at positions
not previously characterized as resistance mutants.
HSV Data
Herpes simplex virus (HSV) is one of the most common
STDs in the United States. Genital herpes is a chronic
life-long infection caused primarily by HSV-2, although
the role of HSV-1 is increasing.46,47 Most patients in-
fected with genital herpes are asymptomatic, and the
clinical presentation is diverse. Because of the availability
of effective antiviral therapy, there is an increased de-
mand for rapid accurate laboratory diagnosis of HSV.
HSV genotyping may aid in tracing of contacts and in
case evaluation.48,49 The MultiCode-RTx HSV-1&2 Kit
(EraGen Biosciences, Madison, WI) is a PCR-based qual-
itative IVD HSV typing assay, using vaginal swab speci-
mens from symptomatic female patients. The assay is not
approved for cerebrospinal fluid (CSF) or any other gen-
ital or oral lesion specimens. The assay uses fluorophore-
labeled HSV-1 and HSV-2 primers that target the glyco-
protein B gene. The extraction methods cleared for the test
include the MagNA Pure LC Instrument and the MagNA
Pure LC Total Nucleic Acid Isolation Kit (Roche Molecular
Diagnostics). The PCR amplification is performed using the
LightCycler 1.2 instrument (Roche Molecular Diagnostics),
after which the HSV genotypes are discriminated by melt
curve analysis. Evaluation of the appropriate specimen/le-
sion and specimen collection procedures is essential be-
cause lesion type and location may affect the sample qual-
ity and the assay performance.
HAI Data
Different HAI assays have specific intended uses, such
as surveillance, presurgical, and diagnostic testing; and
the product insert should be reviewed carefully before
implementation.
MRSA Data
Methicillin resistance is associated with increased mor-
tality in patients with staphylococcal bacteremia.50 Ap-
proximately half of all Staphylococcus aureus pneumonias
in the United States are due to methicillin-resistant S.
aureus (MRSA).51 MRSA ventilator-associated pneumo-
nias also appear to be associated with a higher mortality
rate compared with methicillin-sensitive S. aureus venti-
lator-associated pneumonias.52 Patients colonized with
MRSA (nasal carriers) are also at increased risk of devel-oping MRSA disease and can spread the infection as
well.
For direct MRSA detection from patient samples, the
Xpert MRSA, Xpert SA Nasal Complete assays for the
GeneXpert System (Cepheid, Sunnyvale, CA), the BD
GeneOhm MRSA ACP (BD Diagnostics, La Jolla, CA),
and the LightCycler MRSA Advanced test (Roche Molec-
ular Systems) can be used. The GeneXpert System is a
fully integrated and automated nucleic acid preparation,
amplification, and real-time detection system. The Xpert
SA Nasal Complete (Cepheid) assay can be used for
surveillance of both S. aureus and MRSA carrier status,
which can aid in reducing the risk of HAIs. In a recent
multicenter clinical evaluation, no statistically significant
performance differences were observed between the
Xpert MRSA and MRSA ACP assays compared with cul-
ture.53,54 The recently approved LightCycler MRSA Ad-
vanced test was similarly evaluated compared with the
BD GeneOhmMRSA ACP and had a similar sensitivity
(92.2% and 93.2%, respectively) but a significantly better
specificity (98.9% and 94.2%, respectively).55 All of these
assays target the S. aureus orfX gene sequence incorpo-
rating the insertion site (attBssc) of the staphylococcal
cassette chromosomemec (SCCmec) for the detection of
MRSA. Targeting the mecA alone could result in false
positivity because a large percentage of coagulase-neg-
ative staphylococcus species would also test positive.
False-negative results can occur as the result of novel
SCCmec elements and variants resulting from recombi-
nation. Targeting the orfX region alone can give false-
negative results in those instances of mecA insertion into
other sites (although this is rare).56
Both the BD GeneOhm MRSA ACP and the BD Ge-
neOhm StaphSR assays target the MREJ (types i to vii) of
the SCCmec insertion into the orfX gene and the S. aureus
species-specific nuc gene, which is distinct from the SC-
Cmec cassette. Therefore, false-positive results are re-
duced. However, false-positive results may still occur
because of SCCmec variants with missing or nonfunc-
tional mecA genes (empty cassette variants) and false-
negative results from MREJ variants other than types i
to vii.57
The LightCycler MRSA Advanced assay targets the
sequence incorporating the insertion site of the SCCmec
in the S. aureus orfX gene. Specifically, it targets types 2,
3, and 7 of the right extremity of the SCCmec-orfX junc-
tion. Thus, it may give false-negative results if the tar-
geted right extremity types are not present. This assay
uses the uracil-N-glycosylase enzyme before amplifica-
tion to eliminate any amplicon contamination. The Xpert
MRSA and Xpert SA Nasal Complete assays offer ease of
use, minimal hands-on time, and a closed-tube method of
testing. The assay can also be run either as a single
on-demand assay or in batch mode. In addition, the Xpert
SA Nasal Complete assay has high specificity because of
inclusion of three targets (spa, mecA, and SCCmec), re-
ducing false-positive results due to empty cassette vari-
ants. In this assay, all three targets must be detected for
the assay to give a positive MRSA result. Therefore, co-
agulase-negative staphylococcus species, which may
contain the mecA gene but not the S. aureus–specific spa
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still test positive if there is mixed flora of both methicillin-
sensitive S. aureus and coagulase-negative staphylococ-
cus species in the testing sample; however, the reported
incidence of such cocolonization is low.58
Cultured material can also be tested for the presence
of methicillin-susceptible or resistant S. aureus causing
sepsis (Table 4). Positive blood culture material may be
analyzed by the nonamplified peptide nucleic acid (PNA)
fluorescence in situ hybridization (FISH) method (Ad-
vanDx, Woburn, MA). These pathogen-specific assays
are based on positive blood culture and Gram stain re-
sults for detecting S. aureus and MRSA as soon as the
instrument signal on continuously monitoring blood cul-
ture systems is positive.59–61 Small quantities of positive
blood culture material can also be analyzed using the
multiplex real-time PCR assays [BD GeneOhm StaphSR
(BD Molecular Diagnostics) and Xpert MRSA/SA BC
(Cepheid)]. The latter assay operates under a revised
Corrective Action Letter from Cepheid that instructs lab-
oratories not to report an MRSA-negative result when an
MRSA-negative/SA-positive result is generated on the
Cepheid MRSA/SA Blood Culture Assay. Instead, MRSA-
indeterminate/SA-positive antimicrobial susceptibility
testing pending is the recommendation, with further an-
timicrobial susceptibility testing performed to determine
the MRSA status. The reporting of MRSA-positive/SA-
positive results generated on the Cepheid MRSA/SA
Blood Culture Assay is not affected.
Results can be achieved by real-time PCR, closed,
walk-away systems more rapidly than by more traditional
PCR assays. The commercial assays have excellent sen-
sitivity and specificities when compared with culture. In
particular, genetic excisions within the SCCmec region of
MRSA strains may also yield positive PCR results in the
absence of a functional mecA gene and may cause PCR-
positive but phenotypically methicillin-susceptible S. au-
reus results (empty cassette). This prevalence has dif-
fered by geographical region and appears to be more
common outside the United States.62,63 Decisions on
which assay to implement will depend on laboratory ca-
pabilities, the urgency for the result, and the impact on
patient care. It is recommended that the laboratory rou-
tinely perform clinical correlation of the assay results,
both positive and negative, to keep abreast of diverse
and evolving MRSA strains.
VRE Data
Screening for vancomycin-resistant enterococcus (VRE)
directly from perianal, perirectal, rectal, or stool speci-
mens has been recommended by the CDC, Health Care
Infection Control Practices Advisory Committee (http://
www.cdc.gov/hicpac/mdro/mdro_0.html, last accessed
December 31, 2010) to limit the spread of antimicrobial
resistance within certain high-risk populations. For sur-
veillance of VRE, the XpertvanA (Cepheid) assay can be
performed directly on rectal swab specimens from pa-
tients (Table 2). Gram-positive cocci in pairs and chains–
Enterococcus faecalis/other enterococci PNA FISH (Ad-
vanDx) is also available to identify VRE from positiveblood culture results. Testing for VRE helps identify pa-
tients colonized with resistant enterococci in approxi-
mately 1 to 2 hours. Positive test results indicate the
presence of either the vanA or vanB gene, or vanA alone,
which confers vancomycin resistance in E. faecalis, En-
terococcus faecium, and other bacteria that may colonize
the human intestine. In general, although a positive result
does not imply disease caused by VRE, the presence of
vanA or vanB genes correlates with colonization and clin-
ical correlation is required to determine active VRE dis-
ease. PCR testing should decrease the spread of VRE by
rapid identification and isolation of colonized patients;
however, conventional bacterial cultures may still be re-
quired to isolate VRE from clinical specimens (eg, blood)
for the diagnosis of VRE infection. This approach allows
antimicrobial susceptibility testing for selection of appro-
priate antimicrobial treatment and strain typing of isolates
in outbreak situations.
Clostridium difficile Infection
C. difficile infection is an important cause of diarrhea in
patients who are hospitalized, in long-term care facilities
and receiving antibiotics, and in community settings.64
Four assays are available for the detection of toxigenic
strains of C. difficile (Table 2). The Illumigene C. difficile
assay (Meridian Bioscience Inc., Cincinnati, OH) uses
loop-mediated isothermal amplification technology to de-
tect the pathogenicity toxin A gene (tcdA) in the patho-
genicity locus of toxigenic C. difficile. The C. difficile patho-
genicity locus is a gene segment present in several
known toxigenic C. difficile strains. It codes for both tcdA
and the toxin B gene (tcdB). The test includes a manual
extraction step but does not require costly capital equip-
ment, and results are available in approximately 1 hour.
The Xpert C. difficile (Cepheid), BD GeneOhm Cdiff (BD
Diagnostics), and proGastro Cd (Gen-Probe Prodesse,
Inc., Waukesha, WI) assays are based on real-time PCR
and target tcdB of C. difficile. A positive test result does
not necessarily indicate the presence of viable C. difficile
organisms, but it does indicate the presence of tcdB.
Specimen extraction and amplification for the Xpert C.
difficile test is self-contained and automated, and the re-
sults are available in approximately 45 minutes. The BD
GeneOhm Cdiff assay results are available in 2 hours.
Mutations or polymorphisms in primer- or probe-binding
regions may affect detection of C. difficile tcdA or tcdB
variants, resulting in false-negative results; however, vari-
ant toxigenic C. difficile without tcdB or with a nonfunc-
tional toxin B protein is rare. An assay may be positive for
tcdB without TcdB toxin production (noncytotoxic, IX sub-
type), as reported in community-associated cases in
Canada.65 Because of the enhanced sensitivity of these
amplification methods, testing for C. difficile should be
limited to patients with clinical symptoms of C. difficile
infection. Testing should be limited to diarrheal or loose
stools (ie, those that take the shape of the container), and
the assays should also not be used for test of cure. Assay
performance is unknown for asymptomatic patients.66Tables 2 and 4 list details of assays for HAIs.
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Organism Specimen/sample type Platform/assay (FDA no.)
HCV quantitative EDTA plasma or serum COBAS AmpliPrep/COBAS TaqMan HCV Test (P060030)†
Plasma or serum extracted from blood
collected using EDTA or ACD
VERSANT HCV RNA 3.0 Assay (P020022)‡
HCV qualitative Plasma or serum APTIMA HCV RNA Qualitative Assay (P020011)§
EDTA plasma or serum AMPLICOR HCV test, version 2.0 (P000010)†
EDTA plasma or serum COBAS AMPLICOR HCV test, version 2.0 (P000012)†
HBV quantitative EDTA plasma or serum COBAS TaqMan HBV Test (P050028)†
EDTA plasma or serum RealTime HBV Assay (P080026)¶
GBS Vaginal and rectal swabs incubated in
Lim broth overnight
BD MAX GBS assay and BD MAX System (K090191)
Vaginorectal swab IDI-Strep B (K022504)
Vaginorectal swab Xpert GBS (K060540)**
Directly from vaginal and rectal swabs
or from LIM broth culture
Smart GBS test (K062948)**
Vaginal and rectal swabs incubated in
Lim broth overnight
GBS PNA FISH (K082612)††
Vaginal and anorectal swabs in Lim
broth culture
AccuProbe Group B Streptococcus Culture Identification
Kit (K974572)§
CA, GV, and TV Vaginal sample BD Affirm VPIII Microbial Identification Tests (K931374,
K923133, K931151)
Group A
Streptococcus
Throat swab GASDirect Test (K924715)§
Bacterial identification
from culture
Cultures AccuProbe Neisseria gonorrhoeae (K895583)§
AccuProbe Listeria monocytogenes (K901397)§
Organisms causing
sepsis: GPCC
GPCC-positive cultures BD GeneOhm StaphSR (K071026)
GPCC-positive cultures Xpert MRSA/SA BC (K082140)**
GPCC-positive cultures S. aureus PNA FISH (K060099)††
S. aureus/CNS PNA FISH (K092166)††
GPCC-positive cultures AccuProbe S. aureus (K902213)§
Organisms causing
sepsis: GPCPC
GPCPC-positive cultures AccuProbe Streptococcus pneumoniae (K902908)§
Organisms causing
sepsis: GPCPC
GPCPC-positive cultures E. faecalis/OE PNA FISH (K083074)††
Organisms causing
sepsis: smears from
GNR
GNR-positive cultures EC, PA
PNA FISH (K081309, K092236)††
GNR-positive cultures EC, KP, PA PNA FISH (K101558)††
Organisms causing
sepsis: yeast
Smears made directly from yeast-
positive blood cultures
Candida albicans PNA FISH (K062461)††
Yeast Traffic Light PNA FISH (K080719)††
C. albicans/C. glabrata PNA FISH (K092784)††
Yeast-positive blood cultures AccuProbe Blastomyces dermatitidis (K903201)§
AccuProbe Coccidiodes immitis (K904047)§
AccuProbe Histoplasma capsulatum (K896859)§
Mycobacterial
identification from
cultures
Growth from appropriate solid media
or broth
AccuProbe M. avium (K896494)§
AccuProbe M. avium complex (K897078)§
AccuProbe Mycobacterium gordonae (K896492)§
AccuProbe Mycobacterium intracellulare (K897077)§
AccuProbe Mycobacterium kansasii (K904463)§
AccuProbe MTB complex (K896493)§(table continues)
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Method Target
Linear range (%)*
Sensitivity Specificity
Real-time RT-PCR Transcript of a 244-base sequence in the highly
conserved 5= untranslated region of HCV;
genotypes 1–6
43–69,000,000 IU/mL
bDNA 5=UTR and core regions of the HCV genome 3200–40,000,000 IU/mL
Transcription-mediated amplification 5=UTR of the HCV genome 91.8–100 97.8–98.5
RT-PCR 5=UTR of the HCV genome 92–94 96–97
RT-PCR 5=UTR of the HCV genome 92–94 96–97
Real-time PCR Core-precore region of the HBV genome;
primer pairs to genotypes A–G of HBV and
the precore mutation
20–170,000,000 IU/mL
Real-time PCR Surface (S) gene of the HBV genome; primer
pairs to genotypes A–G of HBV
10–1,000,000,000 IU/mL
Real-time PCR 124-bp region of the cfb gene 95 96.7
Real-time PCR SmartCycler
system**
GBS cfb gene 94 95.9
GeneXpert System (real-time
PCR)**
3= region adjacent to the cfb gene 91.1 96.0
Real-time PCR SmartCycler
system**
DNA 3= region adjacent to the cfb gene Direct from swabs,
81.6
Direct from swabs,
96.4
From Lim broth, 98.7 From Lim broth, 90.4
PNA-FISH 16S rRNA of Streptococcus agalactiae 89.2–100 86.8–100
Culture confirmation; hybridization
protection assay
DNA probe that detects rRNA sequences
unique to S. agalactiae
97.5 99.8
Single-stranded DNA probes,
hybridize with complementary
rRNA target sequences to
form hybrids
rRNA CA, 80.6 CA, 98.2
GV, 83.8 GV, 99.1
TV, 92.8 TV, 99.9
Hybridization protection assay rRNA 91.7 99.3
Hybridization protection assay rRNA 100 100
AccuProbe Listeria monocytogenes (K901397)§ 100 99.7
Real-time PCR SCCmec and mecA gene; nucA gene MRSA % positive
agreement, 100
MRSA % negative
agreement, 98.2–
100
SA % positive
agreement, 98.8–
100
SA % negative
agreement, 96.5
GeneXpert System (real-time
PCR)**
Spa and mecA genes and SCCmec inserted into
S. aureus chromosomal attB insertion site
MRSA, 98.3 MRSA, 99.4
SA, 100 SA, 98.6
FISH assay Species-specific 16S rRNA of S. aureus‡‡ 100 100‡‡
Hybridization protection assay rRNA 100 100
Hybridization protection assay rRNA 100 100
PNA; FISH assay Species-specific 16S rRNA in E. faecalis and
other enterococci§§
% positive agreement
with culture, 100
% negative agreement
with culture, 100
PNA; FISH assay Species-specific rRNA of EC and PA EC, 100 100¶¶
PA, 97.5 100
PNA; FISH assay Species-specific rRNA of EC, KP, and PA EC, 100 EC, 97.5
KP, 98.7 KP, 97.5
PA, 96.9 PA, 97.5
PNA FISH species-specific
probes
16S rRNA of C. albicans 100 100
Hybridization protection assay rRNA 98.1 99.7
98.8 100
100 100
Hybridization protection assay rRNA 99.3 100
99.9 100
98.8 99.7
100 100
98.0 96.8
99.2 99.9(table continues)
ardner
598 Emmadi et al
JMD November 2011, Vol. 13, No. 6Respiratory Tract and CNS Infections
Detection of MTB Complex from Clinical Specimens
Data for the United States describe 11,181 cases of
tuberculosis infections in 2010. Approximately one third
of the 40 million people living with HIV/AIDS worldwide
are coinfected with tuberculosis. People with HIV are up
to 50 times more likely to develop tuberculosis in a given
year than HIV-negative individuals (World Health Organi-
zation, http://www.who.int/tb/challenges/hiv/en/index.html, last
accessed December 31, 2010). Several strains of Myco-
bacterium tuberculosis (MTB) are resistant to multiple an-
tibiotics, and detection of these strains is critical for pa-
tient treatment and public health concerns.
The AMPLIFIED MTD (Mycobacterium Tuberculosis
Direct) Test (Gen-Probe Inc.) (Table 3) is the only FDA-
approved test available for the qualitative detection of
MTB. The assay detects MTB complex rRNA directly from
smear-positive and smear-negative sputum, bronchial
specimens, and tracheal aspirates, with results available
in 4 hours. The sensitivity and specificity of the MTD
assay are 72% and 99.3%, respectively, for smear-neg-
ative patients and 96.9% and 100%, respectively, for
smear-positive patients (package insert, IN0014 revision
L, dated August 2001). Other specimen types (eg, CSF,
blood, and lymph node tissue) are not FDA approved for
use with this assay. Culture of the specimen is still re-
quired given the imperfect sensitivity of the MTD assay
for smear-negative specimens and for susceptibility test-
ing. Non-specific inhibition was reported in 3% to 7% of
sputum specimens. Pollock et al67 have shown that dilu-
tion of the processed sputum sediment by 1:10 using an
MTD reaction buffer overcomes non-specific inhibition
and improves sensitivity of the MTD assay. However, this
dilution technique is not part of the FDA-approved assay.
A positive MTD result in a smear-positive patient helps to
initiate antimycobacterial drug therapy much earlier than
awaiting culture results. The decision to remove patients
from isolation should not be based solely on a negative
MTD test result because of imperfect sensitivity, espe-
Table 4. Continued
Organism Specimen/sample type
Mycoplasma species Tissue culture
*Sensitivity, specificity, linearity range, and percentage positive or negative ag
†Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
‡Obtained from Siemens Healthcare Diagnostics, Deerfield, IL.
§Obtained from Gen-Probe, Inc., San Diego, CA.
¶Obtained from Abbott Molecular, Inc., Des Plaines, IL.
Obtained from BD Diagnostics, Sparks, MD.
**Obtained from Cepheid, Sunnyvale, CA.
††Obtained from AdvanDx, Inc., Woburn, MA.
‡‡False-positive results with Staphylococcus schleiferi may occur bec
§§Enterococcus moraviensis is identified as E. faecalis because of seq
¶¶False-positive results may occur with Shigella species (serogroups A, B, C
ACD, anticoagulant citrate dextrose; bDNA, branched DNA; CA, Cand
cocci in clusters; GPCPC, Gram-positive cocci in pairs and chains; GV, G
Trichomonas vaginalis.cially in smear-negative patients. The limit of detection ofthe AMPLIFIED MTD assay is one colony-forming unit per
test. Because of the global importance of tuberculosis,
nucleic acid tests are recommended by the CDC and the
American Thoracic Society to improve detection and
treatment of this infection (http://www.cdcnpin.org/
scripts/tb/cdc.asp, last accessed December 31, 2010).
Respiratory Tract Viral Infections
Acute respiratory tract infections are the most common
infections in humans, and respiratory tract viruses cause
80% of these infections. Respiratory tract virus infections
range from mild self-limiting upper respiratory tract infec-
tions to severe lower respiratory tract infections. Influenza
causes 200,000 hospitalizations and 36,000 deaths in the
United States annually, and respiratory syncytial virus
(RSV) is the most common cause of severe lower respi-
ratory tract disease in infants and young children world-
wide (World Health Organization, http://www.who.int/
vaccine_research/diseases/ari/en, last accessed Decem-
ber 31, 2010). Influenza A and B and RSV account for the
most serious respiratory tract diseases, with antiviral ther-
apy available for treatment.
The commercially available IVDs for respiratory viral
agents include single or multiple pathogen (multiplex
panel) detection and devices for the identification or typ-
ing of these causative agents (Table 3). Because most of
the respiratory viral agents cause similar symptoms, the
multiplex assays provide the added value of enabling the
simultaneous detection of multiple agents with a single
test. Several multiplex panels are available, and their
applications will be laboratory and patient population
dependent.
Several closed-tube real-time PCR systems are avail-
able for the detection of respiratory tract viruses. These
include the proFlu (Gen-Probe Prodesse, Inc.) test,
which simultaneously detects influenza A and B and RSV,
with a platform designed for a high-throughput labora-
tory. The Verigene System (Nanosphere, Inc., North-
brook, IL) and the Simplexa Flu A/B and RSV (Focus
Platform/assay (FDA no.)
Mycoplasma Tissue Culture NI (MTC-NI)
Rapid Detection System (K860574)§
(table continues)
t with culture data are sourced from FDA submissionmaterial or product inserts.
a single-base mismatch.
entity.
Escherichia albertii, and Escherichia fergusonii because of sequence similarity.
ies; EC, Escherichia coli; GNR, Gram-negative rod; GPCC, Gram-positive
ella vaginalis; KP, Klebsiella pneumonia; PA, Pseudomonas aeruginosa; TV,reemen
ause of
uence id
, or D),
ida specDiagnostics, Inc., Cypress, CA) detect influenza A and B
Review of MID Assays 599
JMD November 2011, Vol. 13, No. 6and RSV. The ProParaFlu (Gen-Probe Prodesse, Inc.)
detects parainfluenza 1, 2, and 3; and the Pro hMPV
(Gen-Probe Prodesse, Inc.) detects human metapneu-
movirus (Table 3). The pro hMPV assay shows 94.1%
sensitivity and 99.3% specificity against a composite ref-
erence method of RT-PCR targeting the nucleocapsid
and fusion genes of hMPV. The ProAdeno (Gen-Probe
Prodesse, Inc.) assay is approved for qualitative detec-
tion of human adenovirus serotypes 1 to 51 in nasopha-
ryngeal specimens. Compared with shell vial culture, the
ProAdeno assay is 98% sensitive and 96% specific.
The ProParaflu assay is approved for qualitative detec-
tion of parainfluenza 1, 2, and 3 from nasopharyngeal
swab specimens. The ability of the ProParaflu assay to
detect parainfluenza virus 1, 2, and 3 ranges from a
sensitivity of 89% to 97% and from a specificity of 99% to
100% when compared with culture. The ProFAST assay
is designed to detect and differentiate influenza A/H1,
influenza A/H3, and the 2009 H1N1 influenza from naso-
pharyngeal specimens. Additional IVDs for influenza A
and H1N1 influenza are the Simplexa Influenza A H1N1
(2009) (Focus Diagnostics, Inc.) and the CDC influenza
assay. However, the CDC assay is not commercially
available. The FDA also cleared the Department of De-
fense biological warfare agent detection device, the
JBAIDS diagnostic system for Influenza A/H5 (avian in-
fluenza) diagnosis. The JBAIDS assay is not available for
general commercial use.
A moderately multiplexed assay, such as the xTAG
Respiratory Viral Panel (Luminex Corp, Austin, TX), de-
tects a panel of 12 viruses and subtypes influenza sea-
sonal H1 and H3 viruses. By using decision tree model-
ing, Mahony et al68 demonstrated that the least costly
strategy to diagnose respiratory tract virus infection was
the xTAG RVP (Luminex Corporation, Austin, TX) test
alone when the prevalence of infection was 11% and
DFA (Direct Fluorescent Antibody) alone when the prev-
alence was11%. The xTAG assay is relatively complex,
and the assay’s open-tube format has the potential for
contamination. The assay is approved for nasopharyn-
geal swab specimens. The assay cannot adequately de-
Table 4. Continued
Method Targe
DNA probe rRNA of Mycoplasma and A
speciestect adenovirus species C or serotypes 7a and 41, andrhinovirus is not differentiated from enterovirus (EV). A
nonsubtypable influenza A result must also be carefully
evaluated because this may be the first indication of an
epidemic caused by a new influenza strain. In addition to
the potential of detecting more viral coinfections, the mul-
tiplex assays, although not FDA cleared for this popula-
tion, may prove useful in the evaluation of immunosup-
pressed patients and in older patients in whom viral titers
may typically be lower.69
CNS Viral Infections
Viral CNS infections usually manifest as meningitis and
encephalitis. Although several microorganisms are asso-
ciated with CNS infections, the only MID IVD available is
for EV, the leading cause of seasonal meningitis. Nucleic
acid testing aids in rapid diagnosis of viral meningitis and
prevents unnecessary antibiotic use and potential repeat
spinal taps, especially in children.70,71 More recently,
rapid nucleic acid amplification tests, including real-time
RT-PCR, nucleic acid sequence-based amplification,
and fully automated systems capable of extraction, am-
plification, and detection, have replaced conventional
RT-PCR methods.72–75 CSF is the diagnostic specimen
for detection of EV in patients with aseptic meningitis.
Pleocytosis and elevation of protein level in CSF are good
markers for CSF infection. The absence of pleocytosis in
CSF may be a good predictor of a negative EV RT-PCR
result in children 2 months. However, elevation of the
CSF protein level is not a good predictor of RT-PCR
positivity for EV.76
Two qualitative IVDs are available for testing CSF
specimens for EV: Xpert EV (Cepheid) and NucliSENS
EasyQ Enterovirus (bioMérieux, l’Etoile, France). The
Xpert EV assay is performed on a GeneXpert System
(Cepheid). In a multicenter evaluation of 102 CSF spec-
imens, the assay had a sensitivity of 97.1% (95% CI,
84.7% to 99.9%) and a specificity of 100% (95% CI,
94.6% to 100%) when compared with culture.74 Although
this initial study demonstrated that moderate amounts of
blood did not interfere with assay performance, a subse-
Linear range (%)*
Sensitivity Specificity
lasma Not applicable Not applicablet
cholepquent study77 indicated that the presence of red blood
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specimens. It also showed that xanthochromia and spec-
imen clotting did not affect results. Specimens with any
invalid results could be diluted at 1:5 or repeat tested
after a freeze-thaw cycle to overcome inhibition, with a
minimal reduction in sensitivity (3.6%). This is an easy-
to-use assay format that affords random access capabil-
ity and minimal hands-on time, with results available in
2.5 hours.
The NucliSENS EasyQ Enterovirus assay (bioMérieux),
a nucleic acid sequence-based amplification, involves
nucleic acid extraction, amplification, and real-time de-
tection of an internal control and EV RNA by Molecular
Beacons that are labeled with two different dyes: 6-FAM
for EV and 6-ROX for the internal control. In a study of 449
prospectively collected CSF specimens tested by cell
culture and NucliSENS EasyQ Enterovirus, method
agreement was 86.4% (95% CI, 79.3% to 91.2%; FDA-
K063261 submission data). In a premarket evaluation
study, 73 this assay was more sensitive than culture
(97.9% versus 65.6%; P  0.001) and inhibition was
noted in only 0.5% of CSF specimens. The GeneXpert
System and nucleic acid sequence-based amplification
assays were compared in a recent multicenter trial for
detection of EV from CSF and had a sensitivity of 100%
and 87.5%, respectively.75 Table 3 lists assays for respi-
ratory tract and CNS infections.
Other Infections
HBV Data
HBV infection is a global public health problem, with 400
million worldwide long-term carriers and up to 25% mor-
tality.78,79 HBV is classified with A–H genotypes, and
prevalence varies greatly by geography and population
subgroups. Because there are significant differences in
genotype-dependent hepatocellular carcinoma, it is es-
sential to detect and quantitate all genotypes. Typically,
the conserved region in the precore/core or N-terminal
portion of the S gene is targeted for target amplification
assays; and multiple probes are used to detect all geno-
types. There is no role for molecular testing in the diag-
nosis of acute HBV other than in the detection of asymp-
tomatic patients during pretransfusion screening of blood
products.
There are two commercial FDA-approved assays for
HBV quantification (Table 4). The COBAS TaqMan HBV
Test for use with the manual High Pure System Viral
Nucleic Acid Kit (Roche Molecular Diagnostics) is ap-
proved for serum and plasma specimen types. Quantifi-
cation of HBV viral DNA is performed using the quantita-
tion standard that is incorporated in each sample. The
dynamic range of the test is 29 to 110,000,000 IU/mL,
with a limit of detection of 10 IU/mL. The RealTime HBV
assay on the m2000 system (Abbott Molecular) has re-
cently been approved to quantify HBV viral load in
plasma and serum. This test has a detection capability
that ranges from 10 to 1 billion IU/mL and spans all knownHBV genotypes (A–H). The same quantitative test should
be used throughout a patient’s treatment course.
HCV Data
Hepatitis C virus (HCV) infection is the most common
cause of chronic viral hepatitis. Nearly 20% of the 4
million carriers develop liver cirrhosis. Viral RNA can be
detected in HCV-infected individuals as early as 1 to 4
weeks before the increase of liver enzymes, and it peaks
in the first 8 to 12 weeks after infection.80 HCV infections
are typically diagnosed by the detection of antibodies
directed against specific HCV antigens. However, HCV
serological tests demonstrate low specificity and may
require confirmation of positive results. Qualitative PCR
assays, such as the FDA-cleared Cobas AMPLICOR HCV
Test, version 2.0 (Roche Molecular Diagnostics), the AP-
TIMA HCV RNA qualitative assay (Gen-Probe Inc.), or the
VERSANT HCV RNA Qualitative assay (Siemens Diag-
nostics), can be used to confirm serological findings.
Treatment for chronic HCV typically consists of a com-
bination of pegylated interferon- and ribavirin, and re-
sponse to therapy is genotype dependent. Quantitative
viral load assays are used to establish viral load at base-
line, monitor viral load during therapy, and determine
response to treatment. Both the rapid and complete early
virologic responses have been used to predict if a patient
will achieve a sustained virologic response. The early
virologic response is defined as a 2-log10 reduction in
HCV RNA levels during the first 12 weeks of therapy. The
rapid and complete early virologic responses are defined
as no virus detected at 4 and 12 weeks after initiation of
antiviral agent, respectively.81 A completely negative test
result for HCV RNA at week 12 (complete early virologic
response) is a better predictor of a sustained virologic
response than a 2-log10 reduction in HCV RNA.
82 A sus-
tained virologic response is achieved when 5 IU/mL
HCV RNA is detected after 24-week treatment. After this,
the treatment is discontinued for genotypes 2 and 3 and
continued for an additional 24 weeks for genotypes 1 and
4. Currently, there are no FDA-approved HCV genotyping
tests. Therefore, the quantitative assays used to measure
HCV viral load need to be sensitive and need to generate
accurate results for all genotypes and subtypes. The
same quantitative test should be used throughout a pa-
tient’s treatment course. The American Association for
the Study of Liver Diseases has published guidelines for
the use of qualitative and quantitative molecular assays
for detection and quantification of HCV RNA in serum and
plasma.83
There are two commercial FDA-approved assays for
HCV quantitation. The COBAS AmpliPrep/COBAS Taq-
Man System (Roche Molecular Diagnostics) is an auto-
mated real-time RT-PCR that targets a highly conserved
sequence in the HCV 5= untranslated region.84,85 The
VERSANT HCV RNA 3.0 Assay (branched DNA) (Sie-
mens Healthcare Diagnostics) is a branched DNA signal
amplification method targeting highly conserved se-
quences in both the 5=UTR and the core gene.86 The
former method has a dynamic range of detection from 25
to 3.9  108 IU of HCV RNA/mL of plasma or serum. The
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HCV RNA/mL of plasma or serum.
Group B Streptococcus
Streptococcus agalactiae [group B Streptococcus (GBS)]
is a leading cause of sepsis, meningitis, and death
among newborn infants in the Western world. Between
10% and 40% of healthy adult women are colonized by
GBS in the genital and gastrointestinal tracts; although
not associated with disease in healthy women, GBS can
cause disease during pregnancy and delivery.87 The
CDC, in collaboration with the American College of Ob-
stetrics and Gynecology and the American Academy of
Pediatrics, issued revised guidelines that included rec-
ommending universal prenatal screening of all pregnant
women between 35 and 37 weeks of gestation to deter-
mine their vaginal/rectal GBS colonization status. The
CDC recommends universal antepartum GBS screening
in all pregnant women, primarily with culture from vaginal-
rectal swabs, to identify candidates for intrapartum pro-
phylaxis to decrease early-onset GBS-related complica-
tions in the newborn.87 Use of vaginal-rectal swabs
improves GBS isolation by 40%, compared with use of
vaginal specimens alone.88 Culture requires up to 36
hours of incubation and, therefore, rapid screening using
molecular test methods may alleviate unnecessary anti-
biotic treatment in patients with preterm labor. A rapid
and sensitive intrapartum real-time PCR assay offers the
advantage of ascertaining the colonization status before
delivery.
Six assays are commercially available for GBS testing
(Table 4), using either direct vaginal-rectal swabs or
these swabs incubated in Lim broth (culture confirma-
tion): AccuProbe Group B Streptococcus culture confir-
mation test (Gen-Probe Inc.), IDI-Strep B (GeneOhm Sci-
ences, San Diego), BD MAX GBS assay (BD
Diagnostics), Smart GBS (Cepheid), Xpert GBS (Ceph-
eid), and the GBS PNA FISH (AdvanDx) assay. The BD
MAX System (BD Diagnostics) is an integrated system
that uses probes (Molecular Beacons), whereas the Gen-
eXpert (Cepheid) system uses TaqMan probes. The
Xpert GBS assay is the only FDA-cleared assay for use
on both intrapartum and antepartum specimens. FDA-
cleared molecular methods allow for increased sensitivity
and a rapid turnaround time. The GeneXpert system fa-
cilitates near-point-of-care analysis in an intrapartum sce-
nario. The BD GeneOhm StrepB and the Smart GBS PCR
assays are not yet automated and require varying de-
grees of hands-on specimen manipulation and sample
preparation. In a high-volume laboratory setting, this may
not be practical. The BD MAX system allows automation
of a PCR assay that is run in a batch mode in the labo-
ratory for antepartum testing. Although PCR tests have
initially been adopted selectively in facilities with suffi-
cient demand and resources, a general recommendation
for their use by the CDC and other agencies would re-
quire the capacity for effective implementation in a wide
range of hospital settings. Some disadvantages of intra-
partum PCR testing include delays in the administration
of antibiotics, pending test results, and lack of an isolatefor susceptibility testing. Susceptibility testing is of par-
ticular concern for women who are allergic to penicillin.
Fungal or Bacterial Identification from Culture
Pathogen-specific rRNA PNA FISH probes can be se-
lected based on a Gram stain result and are available for
bacteria and yeast. These probes have a high impact on
antimicrobial stewardship and HAI.59–61,89–92 Candida
species are a leading cause of both community- and
hospital-associated fungemia. The identification of Can-
dida species in blood cultures is routinely based on pre-
sumptive identification by Gram stain as yeast, followed
by final identification after subculture and biochemical
analysis. There are several PNA FISH assays available
from AdvanDx. The Yeast Traffic Light PNA FISH identi-
fies Candida albicans/Candida parapsilosis, Candida tropi-
calis, and Candida glabrata/Candida krusei and aids in
appropriate drug therapy because of decreased suscep-
tibility (C. glabrata) and inherent resistance (C. krusei) to
fluconazole. Because these MID IVDs do not provide
antimicrobial susceptibility profiles, culture should also
be performed.
AccuProbe kits (Gen-Probe Inc.) performed on culture
specimens can identify several fungi (Coccidioides immi-
tis,Histoplasma capsulatum, and Blastomyces dermatitidis)
that require special handling in biological safety cabi-
nets, thereby decreasing reporting times considerably.
Probes for bacteria include the following: GBS, Strepto-
coccus pneumoniae, S. aureus, Listeria monocytogenes,
and NG. Mycobacterium kits are also available, including
probes to identify MTB complex, Mycobacterium avium
complex, and species-specific M. avium, Mycobacterium
intracellulare, Mycobacterium gordonae, and Mycobacte-
rium kansasii. In contrast to molecular methods, traditional
biochemical methods to speciate Mycobacterium may
take as long as 2 months, whereas these probes can
complete identification in 1 hour. Table 4 lists culture
confirmation and other assays.
Summary and Conclusions
This review is intended to provide the current state-of-
the-art information on FDA- cleared/approved molecular
assays to diagnose infectious diseases. The technology
has evolved rapidly over the past 25 years from a chemi-
luminescent probe performed on the routine bacteriology
bench top to sophisticated and automated platforms
where a patient specimen is extracted and molecular
targets are detected within short turnaround times. Al-
though the application of MID tests in the diagnosis and
management of infectious diseases has greatly improved
health care, it is limited to institutions with certain capac-
ities. The availability of well-characterized FDA-cleared or
FDA-approved MID tests reduces the burden on labora-
tories in developing or validating laboratory-developed
tests, facilitates implementation of molecular testing in
more laboratories, and allows for the standardization and
comparability of tests, thus greatly improving health care
outcomes. Because of the impact on patient care and the
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JMD November 2011, Vol. 13, No. 6evolving technology, we can expect major changes in
molecular testing in the next few years.
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